Latest news

ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

LEUKOTAC® takes next step in paediatric acute steroid-resistant GvHD

Thu, 04/05/2018 - 09:00

ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

LEUKOTAC® at the 44th congress of the European Society for Blood and Marrow Transplantation (EBMT)

Thu, 03/15/2018 - 17:00

A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 program in ophthalmology

Thu, 02/22/2018 - 17:00

ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®, an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

Thu, 10/12/2017 - 17:00

In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

Tue, 07/18/2017 - 17:00

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

ELSALYS BIOTECH expands its team to strengthen its strategy and the development of its programs

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

ELSALYS BIOTECH acquires rights of TRANSGENE’s ANTI-CD115 antibody

Thu, 12/15/2016 - 17:00

Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Subscribe now

Contactez Nous

Headquarters, R&D, Shipping Address : ElsaLys Biotech SA, 317 Avenue Jean Jaurès, 69007 Lyon Administrative site : ElsaLys Biotech SA, Pépinière de Hautepierre 8 avenue Dante, CS 70033 F-67087 Strasbourg contact@elsalysbiotech.com +33 (0)4 37 28 73 00

Latest news

Catégories d'actualités

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Contactez Nous